( R )-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible

Losman, Julie-Aurore, Looper, Ryan E., Koivunen, Peppi, Lee, Sungwoo, Schneider, Rebekka K., McMahon, Christine, Cowley, Glenn S., Root, David E., Ebert, Benjamin L., Kaelin, William G.·2013·Science

DOI 10.1126/science.1231677

Cited by (712)

Items 401–500 of 712

Cancer plasticity: Investigating the causes for this agility
Shubhraneel Saha, Nikita Pradhan, B Neha, Ravikiran Mahadevappa, Shilpi Minocha, Saran Kumar · 2022 · Seminars in Cancer Biology
The Multifaceted Glioblastoma: From Genomic Alterations to Metabolic Adaptations
Addison Quinones, Anne Le · 2021 · Advances in experimental medicine and biology
The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma
Macarena Ines de la Fuente, Mehdi Touat, Martin J. van den Bent, Matthias Preusser, Katherine B. Peters, Robert J. Young, Raymond Y. Huang, Benjamin M. Ellingson, David Capper, Joanna J. Phillips et al. · 2024 · Neuro-Oncology
Pretreatment d-2-hydroxyglutarate serum levels negatively impact on outcome in IDH1-mutated acute myeloid leukemia
J Balss, Christian Thiede, Tilmann Bochtler, Jürgen G. Okun, M Saadati, Axel Benner, Stefan Pusch, Gerhard Ehninger, Markus Andreas Schaich, Anthony Dick Ho et al. · 2015 · Leukemia
Enasidenib-induced differentiation promotes sensitivity to venetoclax in IDH2-mutated acute myeloid leukemia
Séverine Cathelin, David M. Sharon, Amit Subedi, Dan Cojocari, Darren C. Phillips, Joel D. Leverson, Kyle J. MacBeth, Brandon Nicolay, Rohini Narayanaswamy, Sébastien Ronseaux et al. · 2021 · Leukemia
Sumoylation of hypoxia inducible factor-1α and its significance in cancer
Jie Li, Ying Xu, Huike Jiao, Wei Wang, Zhu Mei, Guoqiang Chen · 2014 · Science China Life Sciences
Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic
Muneera Al-Hussaini, John F. DiPersio · 2014 · Expert Review of Hematology
Aspirin Reduces Plasma Concentrations of the Oncometabolite 2-Hydroxyglutarate: Results of a Randomized, Double-Blind, Crossover Trial
David B. Liesenfeld, Akke Botma, Nina Habermann, Réka Tóth, Christoph Weigel, Odilia Popanda, Karel Douglas Klika, John D. Potter, Johanna W. Lampe, Cornelia M. Ulrich · 2016 · Cancer Epidemiology Biomarkers & Prevention
Characterization of cancer-associated IDH2 mutations that differ in tumorigenicity, chemosensitivity and 2-hydroxyglutarate production
Kevin P. Kotredes, Roshanak Razmpour, Evan M. Lutton, Mercedes Alfonso‐Prieto, Servio H. Ramirez, Ana M. Gamero · 2019 · Oncotarget
Metabolic adaptations in cancer progression
Yiming Peng‐Winkler, Sarah‐Maria Fendt · 2025 · Physiological Reviews
Glucose metabolism and its direct action in cancer and immune regulation: opportunities and challenges for metabolic targeting
Bo‐Syong Pan, Che-Chia Hsu, Hsin‐En Wu, Yuan-Ru Chen, Xiaobo Zhou, Shu‐Chi Wang, Chia‐Yang Li, Hui-Kuan Lin · 2025 · Journal of Biomedical Science
Targeting IDH: the next big thing in AML
Mark J. Levis · 2013 · Blood
Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells
Dong Chen, Siyuan Xia, Rukang Zhang, Yuancheng Li, Christopher A. Famulare, Hao Fan, Rong Wu, Mei Wang, Allen C. Zhu, Shannon Elf et al. · 2021 · Molecular Cell
DNA damage in IDH-mutant gliomas: mechanisms and clinical implications
Diana D. Shi, Soummitra Anand, Kalil G. Abdullah, Samuel K. McBrayer · 2022 · Journal of Neuro-Oncology
RIPK3 deficiency blocks R-2-hydroxyglutarate–induced necroptosis in IDH-mutated AML cells
Shuanghong Zhu, Yingwan Luo, Kongfei Li, Chen Mei, Yuxia Wang, Lingxu Jiang, Wei Wang, Qi Zhang, Wenli Yang, Wei Lang et al. · 2024 · Science Advances
The role of mutation of metabolism-related genes in genomic hypermethylation
Joshua J. Waterfall, J. Keith Killian, Paul S. Meltzer · 2014 · Biochemical and Biophysical Research Communications
Identification of a novel metabolic-related mutation (IDH1) in metastatic pancreatic cancer
Jonathan Robert Brody, Cinthya S. Yabar, Mahsa Zarei, Joseph Bender, Lynn McCormick Matrisian, Lola Rahib, Craig Heartwell, Kimberly Mason, Charles J. Yeo, Stephen C. Peiper et al. · 2016 · Cancer Biology & Therapy
Lactate dehydrogenase C is required for the protein expression of a sperm-specific isoform of lactate dehydrogenase A
Mina Dodo, Hiroshi Kitamura, Hiroki Shima, Daisuke Saigusa, Sisca Meida Wati, Nao Ota, Fumiki Katsuoka, Hatsune Chiba, Hiroaki Okae, Takahiro Arima et al. · 2018 · The Journal of Biochemistry
Epigenetic regulation by endogenous metabolite pharmacology
Rhushikesh A. Kulkarni, David C. Montgomery, Jordan L. Meier · 2019 · Current Opinion in Chemical Biology
Pharmacological characterization of TQ 05310, a potent inhibitor of isocitrate dehydrogenase 2 R140Q and R172K mutants
Mingzhao Gao, Hongmei Zhu, Fu Li, Yun Li, Xubin Bao, Haoyu Fu, Haitian Quan, Lei Wang, Liguang Lou · 2019 · Cancer Science
Young-Onset Carcinogenesis – The Potential Impact of Perinatal and Early Life Metabolic Influences on the Epigenome
Savio George Barreto, Stephen Jacob Pandol · 2021 · Frontiers in Oncology
Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation
Desireé Kunadt, Sebastian Stasik, Klaus Hans Metzeler, Christoph Röllig, Christoph Schliemann, Philipp A. Greif, Karsten Spiekermann, Maja Rothenberg‐Thurley, Utz O. Krug, Jan Braess et al. · 2022 · Journal of Hematology & Oncology
Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance
Junhua Lyu, Yuxuan Liu, Lihu Gong, Mingyi Chen, Yazan F. Madanat, Yuannyu Zhang, Feng Cai, Zhimin Gu, Hui Cao, Pranita Kaphle et al. · 2022 · Cancer Discovery
Metabolic Reprogramming and Potential Therapeutic Targets in Lymphoma
Yuyang Pang, Tingxun Lu, Zijun Yidan Xu-Monette, Ken H. Young · 2023 · International Journal of Molecular Sciences
Asperspiropene A, a novel fungal metabolite as an inhibitor of cancer-associated mutant isocitrate dehydrogenase 1
Yan He, Mengzhu Zheng, Qin Li, Zhengxi Hu, Hucheng Zhu, Junjun Liu, Jianping Wang, Yongbo Xue, Hua Li, Yonghui Zhang · 2017 · Organic Chemistry Frontiers
Metabolic Pathway Inhibition in Liver Cancer
Ali Zarrinpar · 2017 · SLAS TECHNOLOGY
Aspartate beta-hydroxylase promotes cholangiocarcinoma progression by modulating RB1 phosphorylation
Chiung‐Kuei Huang, Yoshifumi Iwagami, Jing Zou, Sarah Casulli, Shaolei Lu, Katsuya Nagaoka, Chengcheng Ji, Kousuke Ogawa, Kevin Y. Cao, Jinsong Gao et al. · 2018 · Cancer Letters
Assessing acquired resistance to IDH1 inhibitor therapy by full-exon IDH1 sequencing and structural modeling
Zoltán N. Oltvai, Susan E. Harley, David Ryan Koes, Stephen N. Michel, Erica Dahl Warlick, Andy Nelson, Sophia Louise Yohe, Pawel Mroz · 2021 · Molecular Case Studies
Identification of leukemia stem cell subsets with distinct transcriptional, epigenetic and functional properties
Héléna Boutzen, Alex Murison, Alexa Oriecuia, Suraj Bansal, Christopher Arlidge, Jean C. Y. Wang, Mathieu Lupien, Kerstin B. Kaufmann, John Edgar Dick · 2024 · Leukemia
IDH1R132H Promotes Malignant Transformation of Benign Prostatic Epithelium by Dysregulating MicroRNAs: Involvement of IGF1R-AKT/STAT3 Signaling Pathway
Lili Zhang, Mei Qi, Tingting Feng, Jing Hu, Lin Wang, Xinjun Li, Wei Qiang Gao, Hui Liu, Meng Jiao, Zhen Wu et al. · 2018 · Neoplasia
APC/C CDH1 ubiquitinates IDH2 contributing to ROS increase in mitosis
Surbhi Lambhate, Debanjan Bhattacharjee, Nishant Jain · 2021 · Cellular Signalling
The genetics of myelodysplastic syndromes and the opportunities for tailored treatments
Christina‐Nefeli Kontandreopoulou, Konstantinos Kalopisis, Nora‐Athina Viniou, Panagiotis Theodorou Diamantopoulos · 2022 · Frontiers in Oncology
IDH1 -Mutant Preleukemic Hematopoietic Stem Cells Can Be Eliminated by Inhibition of Oxidative Phosphorylation
Niklas Landberg, Thomas Köhnke, Yang Feng, Yusuke Nakauchi, Amy C. Fan, Miles Hamilton Linde, Daiki Karigane, Kelly SY Lim, Rahul Sinha, Luca Malcovati et al. · 2023 · Blood Cancer Discovery
Complex role of HIF in cancer: the known, the unknown, and the unexpected
Eric L. Huang, Patricia D.B. Tiburcio, Hyunsung Choi · 2014 · Hypoxia
Emerging approaches to target tumor metabolism
Sarah J. Ross, Susan E. Critchlow · 2014 · Current Opinion in Pharmacology
Mitochondrial metabolic remodeling in response to genetic and environmental perturbations
Kate E.R. Hollinshead, Daniel A. Tennant · 2016 · WIREs Systems Biology and Medicine
Which are the most promising targets for minimal residual disease-directed therapy in acute myeloid leukemia prior to allogeneic stem cell transplant?
Brian J. Ball, Eytan M. Stein · 2019 · Haematologica
Molecularly Targeted Therapy in Acute Myeloid Leukemia: Current Treatment Landscape and Mechanisms of Response and Resistance
Curtis Andrew Lachowiez, Courtney Denton Dinardo, Sanam Loghavi · 2023 · Cancers
Isocitrate dehydrogenase 1 and 2 mutations in gliomas
Magdalena Megova Houdova, Jir̆ı́ Drábek, Vladimíra Koudeláková, Radek Trojanec, Ondřej Kalita, Marián Hajdúch · 2014 · Journal of Neuroscience Research
Epigenetic suppression of EGFR signaling in G-CIMP+ glioblastomas
Jie Li, Zachary J. Taich, Amit Goyal, David D. Gonda, Johnny C. Akers, Bandita Adhikari, Kunal S. Patel, Scott R. VandenBerg, Wei Yan, Zhaoshi Bao et al. · 2014 · Oncotarget
Genomic discoveries in adult astrocytoma
Joanna Wang, Chetan Bettegowda · 2015 · Current Opinion in Genetics & Development
D-2-hydroxyglutarate dehydrogenase governs adult neural stem cell activation and promotes histone acetylation via ATP-citrate lyase
Yinghao Liu, Min Wang, Ye Guo, Lei Wang, Weixiang Guo · 2023 · Cell Reports
State of the Art in Low-Grade Glioma Management: Insights From Isocitrate Dehydrogenase and Beyond
Lauren R. Schaff, Maria Ioannou, Marjolein Geurts, Martin J. van den Bent, Ingo K. Mellinghoff, Karisa C. Schreck · 2024 · American Society of Clinical Oncology Educational Book
Mitochondrial bioenergetics as a cell fate rheostat for responsive to Bcl-2 drugs: New cues for cancer chemotherapy
Charlotte Palominos, Sebastián Fuentes-Retamal, Juan Pablo Salazar, Daniela Guzmán‐Rivera, Pablo Correa, Mathias Mellado, Ramiro Araya‐Maturana, Félix A. Urra · 2024 · Cancer Letters
Isocitrate dehydrogenase (IDH)2 R140Q mutation induces myeloid and lymphoid neoplasms in mice
Elena Mylonas, Maxime Janin, Olivia Bawa, Paule Opolon, Muriel D. David, Cyril Quivoron, Olivier Bernard, Chris Ottolenghi, Stephane Debotton, Virginie Penard‐Lacronique · 2014 · Leukemia
Gut insulin action protects from hepatocarcinogenesis in diabetic mice comorbid with nonalcoholic steatohepatitis
Kotaro Soeda, Takayoshi Sasako, K. Enooku, N. Kubota, Naoki Kobayashi, Y. Ikushima, M. Awazawa, R. Bouchi, Gotaro Toda, Tomoharu Yamada et al. · 2023 · Nature Communications
Design, synthesis and biological activity of 3-pyrazine-2-yl-oxazolidin-2-ones as novel, potent and selective inhibitors of mutant isocitrate dehydrogenase 1
Tianfang Ma, Fangxia Zou, Stefan Pusch, Lijun Yang, Qihua Zhu, Yungen Xu, Yueqing Gu, Andreas von Deimling, Xiaoming Zha · 2017 · Bioorganic & Medicinal Chemistry
Identification of a selective inhibitor of IDH2/R140Q enzyme that induces cellular differentiation in leukemia cells
Jiao Chen, Jie Yang, Qingyun Wei, Ling Weng, Fei Wu, Yun Yu Shi, Xiaolan Cheng, Xueting Cai, Chunping Hu, Peng Cao · 2020 · Cell Communication and Signaling
Interaction between transforming Theileria parasites and their host bovine leukocytes
Shahin Tajeri, Malak Haidar, Takaya Sakura, Gordon Langsley · 2021 · Molecular Microbiology
Modular Synthesis of Cell-Permeating 2-Ketoglutarate Esters
Thomas T. Zengeya, Rhushikesh A. Kulkarni, Jordan L. Meier · 2015 · Organic Letters
Discovery of new small molecule inhibitors targeting isocitrate dehydrogenase 1 (IDH1) with blood-brain barrier penetration
Hengyi Cao, Guangya Zhu, Lin Sun, Ge Chen, Xinxin Ma, Xiao Luo, Jidong Zhu · 2019 · European Journal of Medicinal Chemistry
Isocitrate Dehydrogenase Mutant Grade II and III Glial Neoplasms
Ingo K. Mellinghoff, Susan Marina Chang, Kurt A. Jaeckle, Martin J. van den Bent · 2021 · Hematology/Oncology Clinics of North America
The Interplay between Dysregulated Metabolism and Epigenetics in Cancer
Mahmoud Adel Bassal · 2023 · Biomolecules
Molecular Investigation of Isocitrate Dehydrogenase Gene (IDH) Mutations in Gliomas: First Report of IDH2 Mutations in Indian Patients
Bibhu Ranjan Das, Rajiv Tangri, Firoz Ahmad, Arnab Roy, Kamlakar Patole · 2013 · Asian Pacific Journal of Cancer Prevention
Advances in mass spectrometry-based cancer research and analysis: from cancer proteomics to clinical diagnostics
John F. Timms, Oliver J. Hale, Rainer Cramer · 2016 · Expert Review of Proteomics
The role of metabolomics in precision medicine
Soumeya Bekri · 2016 · Expert Review of Precision Medicine and Drug Development
Targeted Differentiation Therapy with Mutant IDH Inhibitors: Early Experiences and Parallels with Other Differentiation Agents
Eytan M. Stein, Katharine E. Yen · 2017 · Annual Review of Cancer Biology
Targeting IDH Mutations in AML: Wielding the Double-edged Sword of Differentiation
Justin S. Becker, Amir Tahmasb Fathi · 2020 · Current Cancer Drug Targets
Management of primary refractory acute myeloid leukemia in the era of targeted therapies
Christine M. McMahon, Alexander E. Perl · 2018 · Leukemia & lymphoma/Leukemia and lymphoma
Hypoxia signaling and oxygen metabolism in cardio-oncology
Alan H. Baik · 2022 · Journal of Molecular and Cellular Cardiology
Rewired Metabolism of Amino Acids and Its Roles in Glioma Pathology
Sirui Chen, Jingjing Jiang, Ao Shen, Ying Miao, Yun‐Feng Cao, Ying Zhang, Peiyu Cong, Peng Gao · 2022 · Metabolites
α-Ketoglutarate dehydrogenase is a therapeutic vulnerability in acute myeloid leukemia
Scott E. Millman, Almudena Chaves Perez, Sudha Janaki‐Raman, Yu-Jui Ho, John P. Morris, Varun K. Narendra, Chi-Chao Chen, Benjamin T. Jackson, Jossie J. Yashinskie, Riccardo Mezzadra et al. · 2025 · Blood
Decreased expression of IDH1-R132H correlates with poor survival in gastrointestinal cancer
Jieying Li, Jianfei Huang, Fang Huang, Qing Jin, Huijun Zhu, Xudong Wang, Meng Chen · 2016 · Oncotarget
The oncometabolite R-2-hydroxyglutarate dysregulates the differentiation of human mesenchymal stromal cells via inducing DNA hypermethylation
Lizhen Liu, Kaimin Hu, Jingjing Feng, Huafang Wang, Shan Fu, Binsheng Wang, Limengmeng Wang, Yulin Xu, Xiaohong Yu, He Huang · 2021 · BMC Cancer
Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis
Stéphane de Botton, Joseph M. Brandwein, Andrew H. Wei, Arnaud Pigneux, Bruno Quesnel, Xavier Thomas, Ollivier Legrand, Christian Récher, Sylvain Chantepie, Mathilde Hunault et al. · 2021 · Cancer Medicine
Metabolomic comparison between cells over‐expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism
He Wen, Hye Rim Cho, Taeho Yun, Hyeonjin Kim, Chul‐Kee Park, Se‐Hoon Lee, Seung Hong Choi, Sunghyouk Park · 2014 · Journal of Neurochemistry
Identification of novel allosteric inhibitors of mutant isocitrate dehydrogenase 1 by cross docking-based virtual screening
Fangxia Zou, Stefan Pusch, Jie Hua, Tianfang Ma, Lijun Yang, Qihua Zhu, Yungen Xu, Yueqing Gu, Andreas von Deimling, Xiaoming Zha · 2017 · Bioorganic & Medicinal Chemistry Letters
Epigenetic Metalloenzymes
Christophe Blanquart, Camille Linot, Pierre‐François Cartron, Daniela Tomaselli, Antonello Mai, Philippe Bertrand · 2018 · Current Medicinal Chemistry
Disruption of the HIF-1 pathway in individuals with Ollier disease and Maffucci syndrome
Sarah R. Poll, Renan Paulo Martin, Elizabeth Wohler, Elizabeth S. Partan, Elizabeth Walek, Shaima Salman, Daniel Groepper, Lisa E. Kratz, Mirlene Cecília Soares Pinho Cernach, Reynaldo Jesús-García et al. · 2022 · PLoS Genetics
Apparent Diffusion Coefficient as Imaging Biomarker for Identifying IDH Mutation, 1p19q Codeletion, and MGMT Promoter Methylation Status in Patients With Glioma
Xiaoxiao Ma, Kun Cheng, Gang Cheng, Chenxi Li, Jinhao Lyu, Yina Lan, Caohui Duan, Xiangbing Bian, Jianning Zhang, Xin Lou · 2023 · Journal of Magnetic Resonance Imaging
Acute myeloid leukemia: advancing clinical trials and promising therapeutics
Naval Guastad Daver, Jörge E. Cortes, Hagop M. Kantarjian, Farhad Ravandi · 2016 · Expert Review of Hematology
Synthesis and biological evaluation of 3-aryl-4-indolyl-maleimides as potent mutant isocitrate dehydrogenase-1 inhibitors
Xiaoqi Liu, Yuanyuan Hu, Anhui Gao, Meng Xu, Lixin Gao, Lei Xu, Yubo Zhou, Jianrong Gao, Qing Ye, Jia Xuan Li · 2018 · Bioorganic & Medicinal Chemistry
Epigenetic deregulation in myeloid malignancies
Hsuan-Ting Huang, María E. Figueroa · 2021 · Blood
ADHFE1 is a MYC-linked oncogene that induces metabolic reprogramming and cellular de-differentiation in breast cancer
Mishra, Prachi, Tang, Wei, Ambs, Stefan · 2018 · Molecular & Cellular Oncology
Isocitrate Dehydrogenase Mutations in Cancer: Mechanisms of Transformation and Metabolic Liability
Kathryn Gunn, Julie-Aurore Losman · 2024 · Cold Spring Harbor Perspectives in Medicine
Deciphering the multifaceted roles and clinical implications of 2-hydroxyglutarate in cancer
Jie Hao, Ziyi Huang, Siyue Zhang, Kefan Song, Juncheng Wang, Chao Gao, Zhiqing Fang, Ning Zhang · 2024 · Pharmacological Research
Therapeutic targeting of chromatin alterations in leukemia and solid tumors
Florian Perner, Tobias Berg, Daniel Sasca, Sophie‐Luise Mersiowsky, Jayant Y. Gadrey, Johanna M. Thomas, Michael W.M. Kühn, Michael Lübbert · 2025 · International Journal of Cancer
IDH1 Mutation Induces HIF-1α and Confers Angiogenic Properties in Chondrosarcoma JJ012 Cells
Xiaoyu Hu, Luyuan Li, Josiane E. Eid, Chao Liu, Jinming Yu, Jinbo Yue, Jonathan C. Trent · 2022 · Disease Markers
Hypoxic regulation of extracellular vesicles: Implications for cancer therapy
Seongkyeong Yoo, Sanga Choi, Iljin Kim, In‐San Kim · 2023 · Journal of Controlled Release
Mechanisms of telomere maintenance and associated therapeutic vulnerabilities in malignant gliomas
Matthew S. Waitkus, Elise N. Erman, Zachary J. Reitman, David M. Ashley · 2024 · Neuro-Oncology
Focus on the epigenome in the myeloproliferative neoplasms
Eun Hee Kim, Omar Ibrahim Abdel-Wahab · 2013 · Hematology
ZEB1 expression is increased in IDH1-mutant lower-grade gliomas
Cody L. Nesvick, Chao Zhang, Nancy A. Edwards, Blake K. Montgomery, Michaela Lee, Chunzhang Yang, Herui Wang, Dongwang Zhu, John D. Heiss, Marsha J. Merrill et al. · 2016 · Journal of Neuro-Oncology
Targeted Therapies for the Evolving Molecular Landscape of Acute Myeloid Leukemia
Khashayar Ahmadmehrabi, Ali R. Haque, Ahmed Aleem, Elizabeth A. Griffiths, Gregory W. Roloff · 2021 · Cancers
Methyl Group Metabolism in Differentiation, Aging, and Cancer
Lars Erichsen, Chantelle Thimm, Simeon Santourlidis · 2022 · International Journal of Molecular Sciences
Frequent reconstitution of IDH2R140Q mutant clonal multilineage hematopoiesis following chemotherapy for acute myeloid leukemia
Daniel H. Wiseman, E L Williams, Deepti P. Wilks, Hui Sun Leong, Tim D.D. Somerville, Michael W. Dennis, Eduard A. Struys, Abdellatif Bakkali, Gajja Sophi Salomons, Tim C. P. Somervaille · 2016 · Leukemia
Bridging Cancer Biology with the Clinic: Comprehending and Exploiting IDH Gene Mutations in Gliomas
Ourania Romanidou, Vassiliki Kotoula, George Fountzilas · 2018 · Cancer Genomics & Proteomics
Cardio-Onco-Metabolism – Metabolic vulnerabilities in cancer and the heart
Anja Karlstaedt, Heinrich Taegtmeyer · 2022 · Journal of Molecular and Cellular Cardiology
Recent Developments in Differentiation Therapy of Acute Myeloid Leukemia
Ugo Testa, Germana Castelli, Elvira Pelosi · 2025 · Cancers
2‐Hydoxyglutarate: D/Riving Pathology in gLiomaS
Daniel Richard Wahl, Sriram Venneti · 2015 · Brain Pathology
Oxidative Demethylation of DNA and RNA Mediated by Non‐Heme Iron‐Dependent Dioxygenases
Lining Lu, Chenxu Zhu, Bo Xia, Chengqi Yi · 2014 · Chemistry - An Asian Journal
Pharmacokinetics and safety of Enasidenib following single oral doses in Japanese and Caucasian subjects
Yan Li, Liangang Liu, Diana Gomez, Jian Chen, Zeen Tong, Maria Palmisano, Simon Yuji Zhou · 2018 · Pharmacology Research & Perspectives
Efficacy and Safety Profile of Ivosidenib in the Management of Patients with Acute Myeloid Leukemia (AML): An Update on the Emerging Evidence
Galia Stemer, Jacob M. Rowe, Yishai Ofran · 2021 · Blood and Lymphatic Cancer Targets and Therapy
Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era?
Roni Tamari, Tariq I. Mughal, Damiano Rondelli, Robert Paul Hasserjian, Vikas K Gupta, Olatoyosi M. Odenike, Veena Devi Salem Fauble, Guido Finazzi, Fabrizio Pane, John O Mascarenhas et al. · 2015 · Bone Marrow Transplantation
Targeted therapy of acute myeloid leukemia
Benedito A. Carneiro, Jessica Kaplan Altman, Jason Benjamin Kaplan, Gert Jan Ossenkoppele, Ronan T. Swords, Leonidas C. Platanias, Francis Joseph Giles · 2015 · Expert Review of Anticancer Therapy
Background Levels of Neomorphic 2-hydroxyglutarate Facilitate Proliferation of Primary Fibroblasts
Aleš Dvořák, Jaroslav Zelenka, Katarína Smolková, Libor Vı́tek, Petr Ježek · 2017 · Physiological Research
Activation of Vitamin D Receptor Pathway Enhances Differentiating Capacity in Acute Myeloid Leukemia with Isocitrate Dehydrogenase Mutations
Marie Sabatier, Emeline Boët, Sonia Zaghdoudi, Nathan Guiraud, Alexis Hucteau, Nathaniel Polley, Guillaume Cognet, Estelle Saland, Laura Lauture, Thomas Farge et al. · 2021 · Cancers
D-2-hydroxyglutarate supports a tolerogenic phenotype with lowered major histocompatibility class II expression in non-malignant dendritic cells and acute myeloid leukemia cells
Kathrin Hammon, Kathrin Renner, Michael Althammer, Florian Voll, Nathalie Babl, Sonja-Maria Decking, Peter J. Siska, Carina Matos, Zugey Elizabeth Cárdenas-Conejo, Karina Mendes et al. · 2024 · Haematologica
Mitochondria and its epigenetic dynamics: Insight into synaptic regulation and synaptopathies
Shiwangi Gupta, Abhinoy Kishore, Vikas Rishi, Aanchal Aggarwal · 2025 · Functional & Integrative Genomics
Emerging drug profile: Krebs cycle and cancer: IDH mutations and therapeutic implications
Sang Min Lee, Arielle Rose Urman, Pinkal M. Desai · 2019 · Leukemia & lymphoma/Leukemia and lymphoma
I-8, a novel inhibitor of mutant IDH1, inhibits cancer progression in vitro and in vivo
Panli Jia, Yao Wu, Hongzhi Du, Lijun Yang, Zhibo Zhang, Tianfang Ma, Li Sun, Shengtao Yuan, Ligong Lu, Xiaoming Zha · 2019 · European Journal of Pharmaceutical Sciences